Project title: Phase 1 study of SurVaxM ™ in survivin-positive NETs
Renuka Iyer, MD Roswell Park Comprehensive Cancer Center
- Status: Completed
- Year(s): 2018
- Grant Type: Pilot
- Research Type: Clinical
- Primary Tumor Site: Small intestine
- Area of Inquiry: Clinical trials
General Description
This study tests the immunotherapy SurVaxM in combination with a somatostatin analog in patients with survivin-expressing NETs. The vaccine targets survivin, a protein that’s often highly expressed in lung, intestinal, and pancreatic NETs and associated with aggressive disease because of its ability to prevent tumor cell death. Many patients with incurable brain cancers on SurvaxM have shown better outcomes than would be expected with standard of care alone.
Additional Details
- City: Buffalo
- State: New York
- Grant Duration: 1 year
DISCLAIMER
NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.